| In 1993, Dayneka received research funding from the [[National Institute of General Medicine Services]] (NIGMS) under the [[National Institutes of Health]] (NIH).((Dayneka, N. L., Garg, V., & Jusko, W. J. (1993). //Comparison of four basic models of indirect pharmacodynamic responses.// Journal of Pharmacokinetics and Biopharmaceutics, 21(4), 457–478. https://doi.org/10.1007/bf01061691)) | In 1993, Dayneka received research funding from the [[National Institute of General Medicine Services]] (NIGMS) under the [[National Institutes of Health]] (NIH).((Dayneka, N. L., Garg, V., & Jusko, W. J. (1993). //Comparison of four basic models of indirect pharmacodynamic responses.// Journal of Pharmacokinetics and Biopharmaceutics, 21(4), 457–478. https://doi.org/10.1007/bf01061691)) She disclosed engaging in consulting activities for [[pharmaceutical_companies:Gilead Sciences]] and [[pharmaceutical_companies:Janssen]].((Kreutzwiser, D., Sheehan, N., Dayneka, N., Lemire, B., Wong, A., Samson, L., & Brophy, J. (2016). //Therapeutic drug Monitoring Guided Raltegravir Dosing for Prevention of Vertical Transmission in a Premature Neonate Born to a Woman Living with Perinatally Acquired HIV.// Antiviral Therapy, 22(6), 545–549. https://doi.org/10.3851/imp3139)) Further research was funded by [[pharmaceutical_companies:AstraZeneca]], [[medical_technology_companies:Cook]], and [[pharmaceutical_companies:Covidien]].((Stewart, P., Dayneka, N., Grenier, S., Stewart, C., Beadow, L., Joseph, G., Mack, D., & Vaillancourt, R. (2009). //In Vitro Study of Esomeprazole Sachet Suspension Administered via Enteral Feeding Tubes.// The Canadian Journal of Hospital Pharmacy, 62(1). https://doi.org/10.4212/cjhp.v62i1.122)) |
